11:00 AM — 12:30 PM
Session 2 Track 3: Commercial/Clinical Case Studies – Synthetic Oligos1:30 PM — 3:00 PM
Session 3 Track 3: Emerging Oligonucleotide CMC Guidance10:00 AM — 11:30 AM
Session 6 Track 3: CMC Considerations in Development of mRNA-based Therapeutics12:45 PM — 2:15 PM
Session 7 Track 3: Challenges Around Oligoneucleotides Control StrategiesHave an account?